IL-17 (Interleukin 17) Basics

IL-17 (interleukin 17) is secreted by a variety of innate cells including macrophages, dendritic cells (DC), natural killer, natural killer T, lymphoid tissue inducer and γδ-T cells.
IL-17 exerts a host-defensive role in many infectious diseases, and it promotes inflammatory pathology in autoimmunity and other settings.
Indeed, pre-clinical studies supporting a role for IL-17 in disease led to current clinical trials designed to block IL-17, the IL-17 receptor (IL-17R) or its inducers (i.e. IL-23, IL-6) in autoimmunity.

IL-17 family product center

In the following, we will mainly discuss IL-17 (interleukin 17) inhibitor.

IL-17 (Interleukin 17) Inhibitor

IL-17 inhibitors are research hotspots, for IL-17 (interleukin 17) plays a role in numerous immune-mediated disorders, such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and autoimmune encephalomyelitis.

Now there are three IL-17 inhibitors on the market.

IL-17 Inhibitor Drug type Indication
Secukinumab Human whole antibody Psoriasis, Psoriatic arthritis, Ankylosing Spondylitis (AS)
brodalumab Human whole antibody Psoriasis vulgaris, Psoriatic arthritis, Psoriatic erythroderma,
Pustular psoriasis, Plaque
ixekizumab Humanized whole antibody Plaque psoriasis, Psoriatic arthritis

Secukinumab, an IL-17 inhibitor, was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on December 26, 2014, then approved by European Medicine Agency (EMA) on January 15, 2015, the U.S. Food and Drug Administration (FDA) on January 21, 2015.

Secukinumab is a human monoclonal IgG1 antibody, which selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.

Brodalumab was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 4, 2016, then approved by the U.S. Food and Drug Administration (FDA) on February 15, 2017.

Brodalumab is an interleukin 17 receptor A (IL17RA) inhibitor, which binds to and blocks IL-17RA and inhibits its interaction with IL-17A, IL-17F and other IL-17s.

Ixekizumab was first approved by the U.S. Food and Drug Administration (FDA) on March 22, 2016, then approved by European Medicine Agency (EMA) on April 25, 2016, approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 4, 2016.

Ixekizumab is an interleukin-17A (IL-17A) antagonist, which selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor.

References

1. Onishi, R. M., & Gaffen, S. L. (2010). Interleukin‐17 and its target genes: mechanisms of interleukin‐17 function in disease. Immunology, 129(3), 311-321.